Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Shapiro, Geoffrey
Item TypeName
Academic Article p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.
Academic Article Cyclin-dependent kinase pathways as targets for cancer treatment.
Academic Article A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Academic Article The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Academic Article Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Academic Article AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Academic Article The physiology of p16(INK4A)-mediated G1 proliferative arrest.
Academic Article Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Academic Article Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
Academic Article Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flavopiridol: Modualtion of cdk targets in clinical samples [abstract]
Academic Article Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.
Academic Article Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Academic Article Direct and indirect modulation of EGFR-mediated growth signaling by Hsp90 inhibition in NSCLCs resistant to EGFR tyrosine kinase inhibitors in vitro and in vivo [abstract]
Academic Article Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Academic Article Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.
Academic Article Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Academic Article The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Academic Article Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Academic Article Bioluminescent imaging of Cdk2 inhibition in vivo.
Academic Article Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Academic Article Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Academic Article Anticancer drug targets: cell cycle and checkpoint control.
Academic Article Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.
Academic Article Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
Academic Article Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
Academic Article Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Academic Article Pharmacodynamics of XL880 a novel spectrum-selective kinase inhibitor (SSKI) administered orally to patients with advanced solid tumors [abstract]
Academic Article A novel p16INK4A transcript.
Academic Article Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.
Academic Article A phase 1 clinical and pharmacokinetic trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients [abstract]
Academic Article Pharmacodynamic assessment of the cyclin-dependent kinase inhibitor flaopiridol: Modulation of cdk targets in clinical samples [abstract]
Academic Article p16INK4A as a human tumor suppressor.
Academic Article The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Academic Article Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Academic Article Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Academic Article Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.
Academic Article Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Academic Article A phase 1 study of a novel spectrum-selective kinase inhibitor (SSKI) XL880, administered orally in pajtients with advanced tumors [abstract]
Academic Article Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.
Academic Article A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Academic Article Phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics of XL880,a VEGFRR and MET kinase inhibitor, administered daily to patients with advanced malignancies [abstract]
Academic Article Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.
Academic Article Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Academic Article Retinoblastoma family member deficiency increases endoreduplication and apoptosis in response to the pan-Aurora kinase inhibitor VE-465 [abstract]
Academic Article Multiple mechanisms of Mcl-1 depletion by the cyclin-dependent kinase inhibitor flavopiridol in mantle cell lymphoma cell lines [abstract]
Academic Article Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Academic Article A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Academic Article A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Academic Article The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function.
Academic Article Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Academic Article Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Concept Mitogen-Activated Protein Kinase 3
Concept Mitogen-Activated Protein Kinase Kinases
Concept Phosphatidylinositol 3-Kinase
Concept Cyclin-Dependent Kinase 2
Concept Protein Kinase Inhibitors
Concept Cyclin-Dependent Kinase Inhibitor p21
Concept Mitogen-Activated Protein Kinase 1
Concept CDC2 Protein Kinase
Concept MAP Kinase Kinase 2
Concept Cyclin-Dependent Kinase 6
Concept Cyclin-Dependent Kinase Inhibitor p16
Concept Cyclin-Dependent Kinase 9
Concept Cyclin-Dependent Kinase Inhibitor p27
Concept Cyclin-Dependent Kinase 4
Concept MAP Kinase Signaling System
Concept Cyclin-Dependent Kinase Inhibitor p18
Concept MAP Kinase Kinase Kinase 3
Concept MAP Kinase Kinase 1
Concept DNA-Activated Protein Kinase
Concept MAP Kinase Kinase Kinase 1
Concept S-Phase Kinase-Associated Proteins
Academic Article A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Academic Article Aurora kinase inhibition as an anticancer strategy.
Academic Article Cyclin-dependent kinase 4/6 inhibition in cancer therapy.
Academic Article A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Academic Article Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
Academic Article Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
Academic Article Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
Academic Article Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
Academic Article Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Academic Article The biology and clinical development of MEK inhibitors for cancer.
Academic Article First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.
Academic Article DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.
Academic Article Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
Academic Article A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Academic Article Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Academic Article Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Academic Article Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Academic Article Targeting CDK4 and CDK6: From Discovery to Therapy.
Academic Article Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Academic Article Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Grant IDENTIFICATION OF CYCLIN C ASSOCIATED PROTEINS
Grant Cyclin-Dependent Kinase Inhibition During S Phase
Grant Dana-Farber/Harvard Cancer Center SPORE in Lung Cancer
Academic Article Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
Academic Article Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Academic Article CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Academic Article A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients.
Academic Article A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
Academic Article A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies.
Academic Article The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Academic Article Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.
Academic Article CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.
Academic Article Genomic Biomarkers Predicting Response to Selective CDK4/6 Inhibition: Progress in an Elusive Search.
Academic Article First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Academic Article RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.
Academic Article Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.
Academic Article Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer.
Academic Article Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Academic Article MicroRNA-Mediated Suppression of the TGF-ß Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.
Academic Article Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Academic Article Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Academic Article The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Academic Article Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Academic Article A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Academic Article Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.
Academic Article CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress.
Academic Article Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
Academic Article A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Search Criteria
  • Elongation Factor 2 Kinase
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.